FUJIFILM ANNOUNCES THE OPENING OF ITS FLEXIBLE MANUFACTURING FACILITY FOR THE PRODUCTION OF CLINICAL AND COMMERCIAL GENE THERAPIESJanuary 24, 2018
FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience focused on the development and manufacture of recombinant biopharmaceuticals and Advanced Therapies, has announced the opening of its state-of-the art Flexible Manufacturing Facility (FBF) in College Station, Texas.Read More
Fujifilm Announces the on-time Completion of Qualification Activities and cGMP Readiness of its SaturnTM High Throughput mAb Manufacturing Facilities in College Station, TexasJanuary 18, 2018
FUJIFILM Corporation (President: Kenji Sukeno) today announced the on-time completion of Qualification activities, enabling commencement of cGMP operations for its Saturn™ mAb manufacturing facilities at FUJIFILM Diosynth Biotechnologies (“FDB”), a world leading cGMP Contract Development and Manufacturing Organization in College Station, Texas. In addition, FDB also announced the expansion of its Apollo™ cell line development capacity at its Billingham, U.K. site.Read More
FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), is pleased to announce that Martin Meeson, President and COO of FUJIFILM Diosynth Biotechnologies U.S.A., is scheduled to present at EBD’s Biotech Showcase 2018 event during the 36th Annual J.P. Morgan Healthcare conference week in San Francisco, California.Read More
FUJIFILM DIOSYNTH BIOTECHNOLOGIES CEO STEVE BAGSHAW IS AWARDED NORTH EAST BUSINESS EXECUTIVE OF THE YEAR 2017November 21, 2017
FUJIFILM Diosynth Biotechnologies, a leading global Contract Development and Manufacturing Organization (CDMO), is pleased to announce that its Chief Executive Officer, Steve Bagshaw, has been awarded “North East Business Executive of the Year 2017”; a prestigious award organized by The Journal in Newcastle, U.K. and its sister paper, The Gazette in Middlesbrough, U.K. and in association with Brewin Dolphin.Read More
FUJIFILM Corporation (President: Kenji Sukeno) is to invest a total of 3.2billion yen on its CDMO* sites in the U.S.A. and the U.K. in order to accelerate the expansion of the company's business for developing and manufacturing biopharmaceuticals** under contract for other parties.
In addition to investing approximately 2.2 billion yen in a GMP facility dedicated to the production of monoclonal antibodies at the FUJIFILM Diosynth Biotechnologies (FDB) site in College Station, Texas, U.S.A., the company is also investing approximately 1.0 billion yen at its Wilton Centre site in Redcar, U.K., to expand the floor area of the development site of production processes for antibodies and install an additional facility. The new investment will expand the existing Saturn mAb™*** Process Development Laboratories dedicated to the development of monoclonal antibodies under FDB's Platform. From Fall 2018 onwards, the new facilities will ramp up operation, bolstering the company's ability to accept orders from its customers for process development and manufacturing in the field of antibodies.
FUJIFILM Diosynth Biotechnologies has announced its opening of the 10,000 square foot, state-of-the-art cell culture Process Development Laboratories in Wilton Centre, Teesside. These laboratories were realized through a JPY1 billion ($9M USD) investment which is part of the greater JPY14 billion ($130M USD) expansion announced by FUJIFILM Corporation in April 2017. A grant from Let’s Grow, which is part of The Regional Growth Fund also contributed to the overall investment as part of FUJIFILM Diosynth Biotechnologies’ continued growth in the Tees Valley. The new facility will bring new sustainable, high tech jobs to the region.
A dedication ceremony was held on September 12, 2017. “Fujifilm’s investment in a new facility on Teesside demonstrates the strength of the UK’s life sciences sector and brings more highly-skilled jobs to the region,” said Lord Prior. “The UK has a very strong science and innovation base and through our Industrial Strategy we are ensuring we continue to be at the forefront of pioneering research and the destination of choice for inward investment.” Lord Prior of Brampton and Mr. Daisuke Matsunaga, Consul General of Japan in the U.K. addressed the audience of local government members and the biotech community during the event.
The new laboratories will be dedicated to support the Saturn™ mAb Platform cell culture Process Development activities. The Saturn mAb Platform™ is designed to enable rapid access to process development and manufacturing capacity.
FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced the successful completion of its 100th program using its pAVEway™ Advanced Protein Expression system which was introduced to the market during the BIO 2007 convention in Boston, Massachusetts.
pAVEway™ was developed by FUJIFILM Diosynth Biotechnologies to enable the reliable and scalable GMP manufacturing of E. coli -based processes. “As a CDMO we established ourselves early on as a leader in microbial process development and manufacturing,” said Andy Topping, Chief Scientific Officer, FUJIFILM Diosynth Biotechnologies. “Completing 100 programs and seeing many of them successfully transferred from the lab into cGMP manufacturing and subsequently to the clinic is fulfilling to everyone at Fujifilm.”
Fujifilm increases production capacity and establishes new process development facilities with JPY14 Billion ($130M USD) investment to support growing market demandApril 18, 2017
FUJIFILM Corporation (President: Kenji Sukeno) will increase production capacity by investing about JPY14 billion ($130m) in the USA and UK in order to expand the business of its BioCDMO Division.Read More
FUJIFILM Diosynth Biotechnologies, has announced the expansion of its Monoclonal Antibody development and manufacturing services with the introduction of its Saturn mAb Platform™.Read More
FUJIFILM Launches Bio CDMO Division to Expand cGMP Contract Development and Manufacturing OperationsFebruary 28, 2017
Aiming to achieve 100 billion yen in revenue by FY2024/MarchRead More
Fujifilm Diosynth Announces Collaboration on a New 20,000-Liter Microbial Biologics Facility for use by its Contract Development and Manufacturing CustomersJune 6, 2016
FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced that it is in the process of establishing a long-term collaboration with MSD, a global biopharmaceutical company known as Merck in the U.S. and Canada, to invest in and operate a large-scale microbial-biologics facility for supply of active pharmaceutical ingredient (API) to its customers.Read More
Construction now complete on new 62,000 square foot facilityRead More
Fujifilm initiates a Phase I clinical trial in the United States of the anti-cancer agent “FF-21101” in Patients with advanced solid tumors such as Lung cancer.January 14, 2016
FUJIFILM Corporation (President: Shigehiro Nakajima) has begun a Phase I clinical trial of its anti-cancer agent FF-21101 in the United States in patients with advanced solid tumors such as lung cancers in 12 January. The trial is carried out at The University of Texas MD Anderson Cancer Center*, one of the world's most distinguished facilities for cancer research and treatment.Read More
Fujifilm Diosynth Biotechnologies breaks ground on laboratory facility in Research Triangle Park, NCJanuary 13, 2015
Construction begins on new 62,000 square foot facilityRead More
FUJIFILM Diosynth Biotechnologies is delighted to announce that Subhash Chaudhary, Director of Strategic Projects, has been awarded an MBE in the Queen's New Year Honours.Read More
Acquisition Enhances Texas' Growing Reputation as a Global Biotechnology Leader
Fujifilm Diosynth Biotechnologies announces the launch of its ‘Apollo™’ mammalian expression platformOctober 9, 2014
FUJIFILM Diosynth Biotechnologies has announced the launch of its new mammalian expression platform, which it has named 'Apollo™'.Read More
FUJIFILM Diosynth Biotechnologies chooses ambr250 System for Optimising Microbial Fermentation To Rapidly Develop Robust Scale-up Processes for Biopharmaceutical Production
Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficileAugust 24, 2014
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today confirmation of exceptional results from the initial phase of cGMP manufacturing of SYN-004, Synthetic Biologics' proprietary oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infections.Read More
FUJIFILM Diosynth Biotechnologies expands cell culture manufacturing capacity with addition of two new 2,000L single-use bioreactorsAugust 19, 2014
FUJIFILM Diosynth Biotechnologies has announced continued expansion of its cell culture manufacturing capabilities with the addition of two 2000L single-use bioreactors. One each of these is being installed at the company's sites in Research Triangle Park (RTP), NC, USA and Billingham, UK.
FUJIFILM Disoynth Biotechnologies continues Expansion of R&D Facilities including addition of Latest High Throughput EquipmentJune 23, 2014
Fujifilm Diosynth Biotechnologies has announced continued expansion of its process development capabilities with the investment of over US$5.6m in new laboratories and equipment at both its Billingham, UK and Research Triangle Park (RTP), NC, USA sites. This includes the first TAP ambr250™ automated bioreactor system for microbial fermentations to be commercially installed in a CDMO at the company’s Billingham, UK site. This investment further demonstrates the company’s commitment to use High Throughput technology and design of experiments to benefit its customers by rapid development of robust scalable processes for their biopharmaceutical production.
FUJIFILM Diosynth Biotechnologies has announced that it has received a renewal of its Manufacturer's Licence from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). The Licence authorises commercial manufacturing at the company's Billingham, UK site, and was received with zero critical or major observations.Read More
FUJIFILM Diosynth Biotechnologies today formally opened its new mammalian cell culture cGMP manufacturing facility at a ceremony performed by HRH The Duke of Gloucester KG GCVO, a member of the UK Royal Family.Read More
FUJIFILM Diosynth Biotechnologies to Evaluate of Synthetic Biologics’ Propietary Beta-Lactamase Enzyme, SYN-004July 18, 2013
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today the initiation of the manufacturing process of the Company's proprietary beta-lactamase enzyme (SYN-004) to target the prevention of Clostridium difficile (C. difficile or C. diff) infections. Pursuant to an agreement with FUJIFILM Diosynth Biotechnologies UK Limited (FUJIFILM), the initial phase of the SYN-004 manufacturing process is underway with the evaluation of beta-lactamase protein expression in FUJIFILM's pAVEway™ platform. SYN-004 will be evaluated for production cell line yields as well as biological activity of the enzyme product.
FUJIFILM Diosynth Biotechnologies has announced that it has commissioned on time its new mammalian cGMP Cell Banking Facility (CBF) at its Billingham, UK site.Read More
FUJIFILM Diosynth Biotechnologies Announces Strategic Alliance with Piramal Healthcare for Production of Antibody Drug ConjugatesOctober 24, 2012
FUJIFILM Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK Ltd, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing niche in the development of biopharmaceuticals.Read More
FUJIFILM Diosynth Biotechnologies has completed the first phase of a 3m ($4.5m) investment in new equipment and laboratories at its Billingham, UK site. This expansion reinforces the commitment to lead the global Biologics CMO industry through continuous innovation and implementation of new technologies, service delivery and quality, as announced by Japan-based parent company, FUJIFILM Corporation.Read More
FUJIFILM Diosynth Biotechnologies and ContraFect Corporation Announce Development and Manufacturing Collaboration for Novel Anti-Staph BiologicOctober 25, 2011
FUJIFILM Diosynth Biotechnologies and ContraFect Corporation announced today that they have signed a contract to support the process development and cGMP manufacture of CF-301, ContraFect’s Staphylococcal-specific bacteriophage lysin. CF-301 is ContraFect’s lead compound and displays potent activity against all forms of Staph infections, including methicillin-resistant (MRSA) and vancomycin-resistant strains (VISA/VRSA).Read More
FUJIFILM Diosynth Biotechnologies is expanding its existing contract manufacturing capabilities with the addition of a 1,000L Xcellerex Single-Use Bioreactor to its RTP, North Carolina facility. This expansion reinforces the commitment to lead the global Biologics CMO industry through continuous innovation and implementation of new technologies, service delivery and quality, as announced by Japan-based parent company, FUJIFILM Corporation.Read More
FUJIFILM Diosynth Biotechnologies has been announced as the new name for the former Merck BioManufacturing Network (known as MSD BioManufacturing Network outside United States and Canada) following completion of its acquisition today by FUJIFILM Corporation of Japan.Read More
FUJIFILM purchases Merck contract manufacturing and service subsidiaries Diosynth and MSD Billingham
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that it has signed a 10-year supply agreement with MSD Biologics (UK) Ltd, part of the Merck BioManufacturing Network, for the production of microplasmin. ThromboGenics anticipates that this deal will meet its long-term commercial needs for bulk drug substance of this novel therapeutic agent.